INSPIREMD INC
NSPRNASDAQTrading Snapshot
- Day Range
- $0.44 – $0.48
- 52-Week Range
- $0.43 – $2.41
- Volume (shares)
- 524,759
- Avg Volume (shares)
- —
- Shares Outstanding
- 46.5M
- Next Earnings
- 2026-11-10
Fundamentals Snapshot
- Annual Revenue
- $9M
- Last Q Revenue
- $2M
- P/E Ratio
- -0.9
- P/S Ratio
- 2.0x
- EPS (TTM)
- $-0.52
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +50.3%
INSPIREMD INC
NSPR
StockOtter · stockotter.spaceAbout INSPIREMD INC
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million
- Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to anticipate in Q4 2026 -
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI, Sept. 04, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensa
InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference
MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present
InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know
InspireMD (NSPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript
InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript
InspireMD Reports Second Quarter 2026 Financial Results
- Company to host investor conference call today, August 17 th , at 8:30am EDT - MIAMI, Aug. 17, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime caro